<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37011639</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1464-3685</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of epidemiology</Title><ISOAbbreviation>Int J Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study.</ArticleTitle><Pagination><StartPage>677</StartPage><EndPage>689</EndPage><MedlinePgn>677-689</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ije/dyad033</ELocationID><Abstract><AbstractText Label="BACKGROUND">Long COVID symptoms occur for a proportion of acute COVID-19 survivors, with reduced risk among the vaccinated and for Omicron compared with Delta variant infections. The health loss attributed to pre-Omicron long COVID has previously been estimated using only a few major symptoms.</AbstractText><AbstractText Label="METHODS">The years lived with disability (YLDs) due to long COVID in Australia during the 2021-22 Omicron BA.1/BA.2 wave were calculated using inputs from previously published case-control, cross-sectional or cohort studies examining the prevalence and duration of individual long COVID symptoms. This estimated health loss was compared with acute SARS-CoV-2 infection YLDs and years of life lost (YLLs) from SARS-CoV-2. The sum of these three components equals COVID-19 disability-adjusted life years (DALYs); this was compared with DALYs from other diseases.</AbstractText><AbstractText Label="RESULTS">A total of 5200 [95% uncertainty interval (UI) 2200-8300] YLDs were attributable to long COVID and 1800 (95% UI 1100-2600) to acute SARS-CoV-2 infection, suggesting long COVID caused 74% of the overall YLDs from SARS-CoV-2 infections in the BA.1/BA.2 wave. Total DALYs attributable to SARS-CoV-2 were 50 900 (95% UI 21 000-80 900), 2.4% of expected DALYs for all diseases in the same period.</AbstractText><AbstractText Label="CONCLUSION">This study provides a comprehensive approach to estimating the morbidity due to long COVID. Improved data on long COVID symptoms will improve the accuracy of these estimates. As data accumulate on SARS-CoV-2 infection sequelae (e.g. increased cardiovascular disease rates), total health loss is likely to be higher than estimated in this study. Nevertheless, this study demonstrates that long COVID requires consideration in pandemic policy planning, given it is responsible for the majority of direct SARS-CoV-2 morbidity, including during an Omicron wave in a highly vaccinated population.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2793-6197</Identifier><AffiliationInfo><Affiliation>Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szanyi</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9706-0194</Identifier><AffiliationInfo><Affiliation>Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blakely</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6995-4369</Identifier><AffiliationInfo><Affiliation>Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Epidemiol</MedlineTA><NlmUniqueID>7802871</NlmUniqueID><ISSNLinking>0300-5771</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Int J Epidemiol. 2023 Jun 6;52(3):967. doi: 10.1093/ije/dyad069</RefSource><PMID Version="1">37196322</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="Y">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">burden of disease</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The Population Interventions Unit is expected to receive funding from Moderna Inc. to
conduct research on COVID-19 vaccine effectiveness in Victoria, Australia. No other
conflicts of interest are declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37011639</ArticleId><ArticleId IdType="pmc">PMC10244043</ArticleId><ArticleId IdType="doi">10.1093/ije/dyad033</ArticleId><ArticleId IdType="pii">7100842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen IH, Magnus P, Trogstad L.. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. Eur J Epidemiol 2022;37:539&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8872922</ArticleId><ArticleId IdType="pubmed">35211871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med 2021;27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarialiabad H, Taghrir MH, Abdollahi A. et al. Long COVID, a comprehensive systematic scoping review. Infection 2021;49:1163&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG. et al.; ISB-Swedish COVID-19 Biobanking Unit. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185:881&#x2013;95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics (ONS). Self-Reported Long COVID
After Two Doses of a Coronavirus (COVID-19) Vaccine in the UK: 26 January 2022.
ONS. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidaftertwodosesofacoronaviruscovid19vaccineintheuk/26january2022
(26 January 2022, date last accessed).</Citation></Reference><Reference><Citation>Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. J Clin Epidemiol 2022;142:54&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547965</ArticleId><ArticleId IdType="pubmed">34715312</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Institute of Health and Welfare (AIHW). The First Year of COVID-19 in Australia: Direct and Indirect Health Effects. Canberra: AIHW, 2021.</Citation></Reference><Reference><Citation>Angeles MR, Wanni Arachchige Dona S, Nguyen HD, Le LK, Hensher M.. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan. BMC Public Health 2022;22:757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009167</ArticleId><ArticleId IdType="pubmed">35421963</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen AIV, Spiliopoulos L, Bager P. et al. Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population. Nat Commun 2022;13:4213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn&#xfa;sd&#xf3;ttir I, Lovik A, Unnarsd&#xf3;ttir AB. et al.; COVIDMENT Collaboration. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health 2022;7:E406&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920517</ArticleId><ArticleId IdType="pubmed">35298894</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnood SA, Shafran R, Bennett SD. et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect 2022;84:158&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604800</ArticleId><ArticleId IdType="pubmed">34813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T, Lim SS, Abbafati C. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990&#x2013;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567026</ArticleId><ArticleId IdType="pubmed">33069326</ArticleId></ArticleIdList></Reference><Reference><Citation>van Baal PHM, Hoeymans N, Hoogenveen RT, de Wit AG, Westert GP.. Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy. PHM 2006;4:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1523368</ArticleId><ArticleId IdType="pubmed">16606448</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahm C, Seneghini M, G&#xfc;sewell S. et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort. Clin Infect Dis 2022;75:e1011&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383387</ArticleId><ArticleId IdType="pubmed">35090015</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler L, Gazit S, Pinto Y. et al. Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study. Scand J Prim Health Care 2022;40:342&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9848375</ArticleId><ArticleId IdType="pubmed">36314555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A. et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun 2022;13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG. et al.; Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022;328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S.. Long COVID symptoms and duration in SARS-CoV-2 positive children&#x2014;a nationwide cohort study. Eur J Pediatr 2022;181:1597&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742700</ArticleId><ArticleId IdType="pubmed">35000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB. et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky JP, Govindarajulu U, Bagiella E. et al. Association of vaccination with the persistence of post-COVID symptoms. J Gen Intern Med 2022;37:1748&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ.. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022;399:2263&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakely T, Thompson J, Bablani L. et al. Association of simulated COVID-19 policy responses for social restrictions and lockdowns with health-adjusted life-years and costs in Victoria, Australia. JAMA Health Forum 2021;2:e211749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796885</ArticleId><ArticleId IdType="pubmed">35977202</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID Live. Hospitalizations: Current Cases Admitted to
Hospital. 2022. https://covidlive.com.au/report/hospitalized (1 June 2022, date last
accessed).</Citation></Reference><Reference><Citation>Tobin RJ, Wood JG, Jayasundara D. et al. Hospital length of stay in a mixed Omicron and Delta epidemic in New South Wales, Australia. medRxiv. doi:10.1101/2022.03.16.22271361, 19 March 2022, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.16.22271361</ArticleId><ArticleId IdType="pmc">PMC9844941</ArticleId><ArticleId IdType="pubmed">36650474</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L. et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022;399:1618&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Institute of Health and Welfare (AIHW). Australian Burden of Disease Study: Impact and Causes of Illness and Death in Australia 2018. Canberra: AIHW, 2021.</Citation></Reference><Reference><Citation>COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: epidemiology report 60: reporting period ending 10 April 2022. Commun Dis Intell (2018) 2022;46:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35538650</ArticleId></ArticleIdList></Reference><Reference><Citation>
Institute for Health Metrics and Evaluation (IHME). GBD
Results. 2022. https://vizhub.healthdata.org/gbd-results/ (2 June 2022, date last
accessed).</Citation></Reference><Reference><Citation>
New South Wales Ministry of Health. COVID-19 Weekly Surveillance
Reports &#x2013; Archive. 2022. https://www.health.nsw.gov.au/Infectious/covid-19/Pages/weekly-reports-archive.aspx
(1 June 2022, date last accessed).</Citation></Reference><Reference><Citation>
Australian Bureau of Statistics (ABS). National, State and
Territory Population. 2022. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release
(14 Nov 2022, date last accessed).</Citation></Reference><Reference><Citation>
COVID Live. New Cases: Total Cases and New Last 24hrs.
2022. https://covidlive.com.au/report/cases (1 June 2022, date last
accessed).</Citation></Reference><Reference><Citation>
Ting I, Workman M, Shatoba K, Hutcheon S, Palmer A;
Australian Broadcasting Corporation. Charting the Spread of
COVID-19 in Australia. 2020.  (updated 25 May 2022). https://www.abc.net.au/news/2020-03-17/coronavirus-cases-data-reveals-how-covid-19-spreads-in-australia/12060704-newcases
(1 June 2022, date last accessed).</Citation></Reference><Reference><Citation>
Department of Health and Aged Care, Commonwealth of Australia.
COVID-19 Vaccine Rollout &#x2013; 10 December 2021. 2021.
https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-10-december-2021
(18 November 2022, date last accessed).</Citation></Reference><Reference><Citation>
European Burden of Diseae Network (EBoDN). Burden of Disease of
COVID-19: Protocol for Country Studies. 2022. https://www.burden-eu.net/docs/covid19-bod-protocol.pdf (27 September 2022,
date last accessed).</Citation></Reference><Reference><Citation>Wyper GMA, Fletcher E, Grant I. et al. Measuring disability-adjusted life years (DALYs) due to COVID-19 in Scotland, 2020. Arch Public Health 2022;180:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972687</ArticleId><ArticleId IdType="pubmed">35365228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri S, Calleja N, Devleesschauwer B, Wyper GMA.. Estimating the direct Covid-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health 2021;21:1827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501913</ArticleId><ArticleId IdType="pubmed">34627228</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran DP, Pires SM, Wyper GMA, Devleesschauwer B, Cuschieri S, Kabir Z.. Estimating the direct disability-adjusted life years associated with SARS-CoV-2 (COVID-19) in the Republic of Ireland: the first full year. Int J Public Health 2022;267:1604699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200950</ArticleId><ArticleId IdType="pubmed">35719731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Hartman TC, Rosmalen JGM, Lifelines Corona Research Initiative Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 2022;400:452&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M. et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 2022;13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V. et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z.. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022;28:583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022;604:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J. et al.; COVERSCAN Study Investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open 2021;11:e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>